Today, however, criteria for the diagnosis of AKI are subject to change, and the sole increase beyond a given threshold of a biomarker such as NGAL may allow clinicians not only to suspect a risk for AKI but also to make a diagnosis of subclinical AKI or non-creatinine-increase AKI [4-6,10,11]. This evidence concerns the gene LCN2 and acute kidney injury.